Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression.
Brain, behavior, and immunity July 5, 2026 Bruno Pedraz-Petrozzi, Marta Marszalek-Grabska, Emilia Fornal et al.
Treatment-resistant depression (TRD) remains a major clinical challenge, with highly variable responses to ketamine. Immune activation characterizes a subset of patients with TRD. The kynurenine pathway (KP), which integrates immunometabolic signals with glutamatergic neurotransmission, may provide candidate biomarkers to inform personalized treatment. We investigated whether KP metabolites and...